SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 123 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $145 | -30.6% | 10,000 | 0.0% | 0.01% | -30.0% |
| Q2 2023 | $209 | -0.9% | 10,000 | 0.0% | 0.01% | -9.1% |
| Q1 2023 | $211 | -17.3% | 10,000 | 0.0% | 0.01% | -21.4% |
| Q4 2022 | $255 | -99.9% | 10,000 | 0.0% | 0.01% | +7.7% |
| Q3 2022 | $240,000 | +25.0% | 10,000 | 0.0% | 0.01% | +30.0% |
| Q2 2022 | $192,000 | +10.3% | 10,000 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $174,000 | -20.5% | 10,000 | 0.0% | 0.01% | -11.1% |
| Q4 2021 | $219,000 | +14.7% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $191,000 | +11.0% | 10,000 | 0.0% | 0.01% | +12.5% |
| Q2 2021 | $172,000 | -23.2% | 10,000 | 0.0% | 0.01% | -33.3% |
| Q1 2021 | $224,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |